Clinical Trials Browser

Cytokine Release Syndrome × Plasma cell × 90 days × Clear all

NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Completed

24 enrolled 8 charts

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07499128 2026-06-01

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Phase NA Enrolling by invitation

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Multiple Myeloma, Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07609940 2026-05-27

POPLIN

Phase 4 Not yet recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT06421675 2026-04-27

EMBRACE

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma